WO2000063230A3 - 49 proteines secretees humaines - Google Patents

49 proteines secretees humaines Download PDF

Info

Publication number
WO2000063230A3
WO2000063230A3 PCT/US2000/007677 US0007677W WO0063230A3 WO 2000063230 A3 WO2000063230 A3 WO 2000063230A3 US 0007677 W US0007677 W US 0007677W WO 0063230 A3 WO0063230 A3 WO 0063230A3
Authority
WO
WIPO (PCT)
Prior art keywords
secreted proteins
human secreted
proteins
novel human
relates
Prior art date
Application number
PCT/US2000/007677
Other languages
English (en)
Other versions
WO2000063230A2 (fr
Inventor
Craig A Rosen
Steven M Ruben
George Komatsoulis
Original Assignee
Human Genome Sciences Inc
Craig A Rosen
Steven M Ruben
George Komatsoulis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU67457/00A priority Critical patent/AU6745700A/en
Priority to JP2000612320A priority patent/JP2002541833A/ja
Priority to CA002364209A priority patent/CA2364209A1/fr
Priority to EP00955227A priority patent/EP1171462A2/fr
Application filed by Human Genome Sciences Inc, Craig A Rosen, Steven M Ruben, George Komatsoulis filed Critical Human Genome Sciences Inc
Publication of WO2000063230A2 publication Critical patent/WO2000063230A2/fr
Publication of WO2000063230A3 publication Critical patent/WO2000063230A3/fr
Priority to US10/105,299 priority patent/US7368527B2/en
Priority to US10/670,186 priority patent/US20070031842A1/en
Priority to US10/670,185 priority patent/US20070015162A1/en
Priority to US10/868,184 priority patent/US20070048818A1/en
Priority to US10/994,608 priority patent/US20070048297A1/en
Priority to US11/781,665 priority patent/US20070298491A1/en
Priority to US12/753,401 priority patent/US8410248B2/en
Priority to US13/848,789 priority patent/US20130203164A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne de nouvelles protéines sécrétées humaines et des acides nucléiques contenant les régions codantes des gènes qui codent pour ces protéines. L'invention concerne également des vecteurs, des cellules hôtes, des anticorps et des procédés recombinants permettant de produire des protéines sécrétées humaines. L'invention concerne en outre des méthodes de diagnostic et de traitement permettant de diagnostiquer et de traiter les maladies, troubles et/ou états pathologiques associés à ces nouvelles protéines sécrétées humaines.
PCT/US2000/007677 1999-03-12 2000-03-23 49 proteines secretees humaines WO2000063230A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AU67457/00A AU6745700A (en) 1999-03-26 2000-03-23 49 human secreted proteins
JP2000612320A JP2002541833A (ja) 1999-03-26 2000-03-23 ４９個のヒト分泌タンパク質
CA002364209A CA2364209A1 (fr) 1999-03-26 2000-03-23 49 proteines secretees humaines
EP00955227A EP1171462A2 (fr) 1999-03-26 2000-03-23 49 proteines secretees humaines
US10/105,299 US7368527B2 (en) 1999-03-12 2002-03-26 HADDE71 polypeptides
US10/670,186 US20070031842A1 (en) 1999-03-12 2003-09-25 379 human secreted proteins
US10/670,185 US20070015162A1 (en) 1999-03-12 2003-09-25 99 human secreted proteins
US10/868,184 US20070048818A1 (en) 1999-03-12 2004-06-16 Human secreted proteins
US10/994,608 US20070048297A1 (en) 1999-03-12 2004-11-23 Human secreted proteins
US11/781,665 US20070298491A1 (en) 1999-03-12 2007-07-23 Human Secreted Proteins
US12/753,401 US8410248B2 (en) 1999-03-12 2010-04-02 HWBAO62 polypeptides
US13/848,789 US20130203164A1 (en) 1999-03-12 2013-03-22 Human Secreted Proteins

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US12660199P 1999-03-26 1999-03-26
US15437399P 1999-09-17 1999-09-17
US17606400P 2000-01-14 2000-01-14
US60/126,601 2000-01-14
US60/176,064 2000-01-14
US60/154,373 2000-01-14

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2000/007725 Continuation-In-Part WO2000058358A1 (fr) 1999-03-12 2000-03-23 Proteines humaines secretees (49)
PCT/US2000/007726 Continuation-In-Part WO2000058336A1 (fr) 1999-03-12 2000-03-23 50 proteines humaines secretees

Related Child Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2000/007725 Continuation-In-Part WO2000058358A1 (fr) 1999-03-12 2000-03-23 Proteines humaines secretees (49)
PCT/US2000/007726 Continuation-In-Part WO2000058336A1 (fr) 1999-03-12 2000-03-23 50 proteines humaines secretees
US95008201A Continuation-In-Part 1999-03-12 2001-09-12
US95008301A Continuation-In-Part 1999-03-12 2001-09-12

Publications (2)

Publication Number Publication Date
WO2000063230A2 WO2000063230A2 (fr) 2000-10-26
WO2000063230A3 true WO2000063230A3 (fr) 2001-02-08

Family

ID=27383444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007677 WO2000063230A2 (fr) 1999-03-12 2000-03-23 49 proteines secretees humaines

Country Status (5)

Country Link
EP (1) EP1171462A2 (fr)
JP (1) JP2002541833A (fr)
AU (1) AU6745700A (fr)
CA (1) CA2364209A1 (fr)
WO (1) WO2000063230A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573095B1 (en) 1998-04-29 2003-06-03 Genesis Research & Development Corporation Limited Polynucleotides isolated from skin cells
CA2398396A1 (fr) * 2000-01-25 2001-08-02 Hyseq, Inc. Methodes et matieres concernant des polypeptides et polynucleotides similaires a alpha de facteur de croissance de transformation
AU2001260847A1 (en) * 2000-05-24 2001-12-03 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
ATE350396T1 (de) * 2001-05-25 2007-01-15 Nymox Corp Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
CN100475843C (zh) 2001-07-19 2009-04-08 尼莫克斯股份有限公司 有效***和其它需要除去或破坏细胞的疾病的肽
EP1847550A3 (fr) * 2001-07-19 2008-01-09 Nymox Corporation Peptides actives dans le traitement des tumeurs et autre conditions requérant la suppression ou la destruction de cellules
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
KR100535543B1 (ko) * 2002-09-13 2005-12-08 현대자동차주식회사 스로틀 밸브 동결 방지장치
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005256A1 (fr) * 1990-09-18 1992-04-02 Genetics Institute, Inc. Facteur stimulateur de cellules tueuses naturelles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005256A1 (fr) * 1990-09-18 1992-04-02 Genetics Institute, Inc. Facteur stimulateur de cellules tueuses naturelles

Also Published As

Publication number Publication date
WO2000063230A2 (fr) 2000-10-26
AU6745700A (en) 2000-11-02
EP1171462A2 (fr) 2002-01-16
CA2364209A1 (fr) 2000-10-26
JP2002541833A (ja) 2002-12-10

Similar Documents

Publication Publication Date Title
EP1053245A4 (fr) 45 proteines humaines secretees
WO1998039446A3 (fr) 70 proteines humaines secretees
WO1998039448A3 (fr) 186 nouvelles proteines secretees
WO1998040483A3 (fr) 28 proteines secretees par l'homme
WO1998031800A3 (fr) Proteines humaines
WO2001032910A3 (fr) 27 proteines humaines secretees
WO2001036432A3 (fr) 18 proteines secretees humaines
WO1998045712A3 (fr) 20 proteines humaines secretees
CY1111950T1 (el) 32 ανθρωπινες εκκρινομενες πρωτεϊνες
WO2001012776A3 (fr) 18 proteines secretees humaines
WO2001034768A3 (fr) 15 proteines secretees humaines
WO2000017222A8 (fr) 31 proteines humaines secretees
WO2000077026A8 (fr) 49 proteines secretees humaines
WO2000052136A3 (fr) Enzymes de glycosylation humaines
WO2000063230A3 (fr) 49 proteines secretees humaines
WO2000073323A3 (fr) Polynucléotides et polypeptides adam
WO2001062891A3 (fr) 207 proteines humaines secretees
EP1042342A4 (fr) 53 proteines secretees humaines
WO2000058339A3 (fr) 50 proteines humaines secretees
WO2001012775A3 (fr) 25 proteines secretees humaines
WO2000043495A3 (fr) Proteines humaines secretees (33)
WO2000061624A8 (fr) 48 proteines secretees humaines
WO2000061596A8 (fr) 50 proteines humaines secretees
WO2003052377A9 (fr) 41 proteines secretees humaines
WO2002099066A3 (fr) 20 proteines humaines secretees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2364209

Country of ref document: CA

Ref country code: CA

Ref document number: 2364209

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 612320

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000955227

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000955227

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000955227

Country of ref document: EP